[Coursera] Mining Massive Datasets (Stanford University) (mmds)

The main memory database system (MMDS) market is experiencing robust growth, driven by the increasing demand for real-time data processing and analytics across diverse sectors. The market, estimated at $5 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033, reaching approximately $15 billion by 2033. This expansion is fueled by several key factors. The surge in big data volume and velocity necessitates faster data processing capabilities, a key strength of MMDS. Furthermore, the growing adoption of cloud computing and the rise of in-memory computing technologies are accelerating the market's trajectory. Businesses across finance, telecommunications, and e-commerce are increasingly adopting MMDS to gain real-time insights, optimize operations, and enhance customer experiences. The competitive landscape is marked by established players like SAP, Oracle, and IBM, alongside emerging innovative companies offering specialized solutions. While high initial investment costs and the need for specialized expertise can pose challenges, the overall market outlook remains positive, owing to the increasing value proposition of MMDS in enhancing operational efficiency and delivering actionable intelligence. The competitive landscape within the MMDS market is characterized by a blend of established technology giants and agile specialized vendors. Companies like SAP, Oracle, and IBM leverage their existing customer bases and extensive ecosystems to offer integrated MMDS solutions. However, smaller companies such as MemSQL, Exasol, and Kognitio are aggressively innovating, focusing on specific niche markets and offering highly specialized performance capabilities. This dynamic environment promotes healthy competition, driving innovation and pushing the boundaries of performance and scalability. Regional variations in adoption rates are anticipated, with North America and Europe likely leading the market due to higher technological adoption and stronger regulatory frameworks supporting data-driven decision-making. However, emerging economies in Asia-Pacific and Latin America are poised for significant growth, driven by increasing digitalization and the expansion of cloud computing infrastructure. Strategic partnerships and acquisitions are expected to shape the market's future trajectory, as companies seek to expand their product portfolios and broaden their reach.

The global market for Methylene Methanedisulfonate (MMDS) is projected to reach a value of XXX million by 2033, growing at a CAGR of XX% during the forecast period. The market is primarily driven by the increasing demand for MMDS as an electrolyte additive in lithium-ion batteries, as well as its use as a drug intermediate in the pharmaceutical industry. Electrolyte additives are used to improve the performance and stability of lithium-ion batteries, while drug intermediates are used as starting materials in the synthesis of pharmaceutical drugs. Key trends influencing the MMDS market include the rising popularity of electric vehicles (EVs) and hybrid electric vehicles (HEVs), which use lithium-ion batteries as their power source. The growth of the EV and HEV market is expected to drive the demand for MMDS as an electrolyte additive. Additionally, the increasing prevalence of chronic diseases, such as cancer and diabetes, is driving the demand for MMDS as a drug intermediate for the production of pharmaceuticals.

Global Methylene Methanedisulfonate MMDS market size 2025 is $227.9 Million whereas according out published study it will reach to $372.468 Million by 2033. Methylene Methanedisulfonate MMDS market will be growing at a CAGR of 6.333% during 2025 to 2033.

Explore the historical Whois records related to mmds-jo.net (Domain). Get insights into ownership history and changes over time.

Передатчики, использующие технологию MMDS, LMDS, MWS (MVDS). Статистика с портала ЕМИСС (fedstat.ru).

The Methylene Methanedisulfonate (MMDS) market is experiencing robust growth, driven by its increasing applications in diverse sectors. While precise market size figures for 2019-2024 are unavailable, a reasonable estimation based on industry trends and the provided CAGR (let's assume a conservative CAGR of 8% for illustrative purposes) suggests a substantial market. Assuming a 2025 market size of $150 million (a plausible figure given the listed companies and applications), the market is projected to reach approximately $250 million by 2033, demonstrating significant growth potential. Key drivers include the rising demand for high-purity MMDS in electrolyte additives for advanced batteries, its crucial role as a drug intermediate in pharmaceutical manufacturing, and its expanding use in other specialty chemicals. The demand for high-purity grades (above 99.9%) is particularly strong, fueled by the stringent quality requirements in these applications. However, potential restraints include fluctuations in raw material prices and the competitive landscape with alternative chemicals. The market's segmentation by application (electrolyte additives, drug intermediates, others) and purity levels (above 98.0%, above 99.0%, above 99.9%) highlights the diverse opportunities within the MMDS market. Geographic expansion, particularly in Asia-Pacific, is expected to contribute significantly to future market growth, driven by increasing industrial activity and manufacturing capacity in regions like China and India. The competitive landscape is characterized by a mix of established chemical companies and specialized manufacturers. Companies like Fujian Chuangxin Science and Develops Co., Ltd., and Hubei Chushengwei Chemistry Co., Ltd., are likely key players, given their presence in the market. However, the lack of precise market share data prevents a detailed competitive analysis. The future of the MMDS market is bright, with continued growth expected as technological advancements and emerging applications further drive demand. Strategic partnerships, research and development initiatives, and expansion into new geographical markets will be crucial for companies seeking to capitalize on this expanding market opportunity. Further market research into specific application segments and regional markets would provide a more precise understanding of market dynamics and growth trajectory.

Learn more about Market Research Intellect's Methylene Methanedisulfonate (MMDS) Sales Market Report, valued at USD 150 million in 2024, and set to grow to USD 250 million by 2033 with a CAGR of 7.5% (2026-2033).

Brazil Pay TV: by Technology: MMDS data was reported at 266.000 Unit in Dec 2019. This records a decrease from the previous number of 270.000 Unit for Nov 2019. Brazil Pay TV: by Technology: MMDS data is updated monthly, averaging 9,384.500 Unit from Jan 2012 (Median) to Dec 2019, with 96 observations. The data reached an all-time high of 234,149.000 Unit in Jan 2012 and a record low of 264.000 Unit in Oct 2019. Brazil Pay TV: by Technology: MMDS data remains active status in CEIC and is reported by National Telecommunication Agency. The data is categorized under Global Database’s Brazil – Table BR.TB015: Pay TV: Evolution of Pay TV Accesses by Technology.

The Methylene Methanedisulfonate (MMDS) market is experiencing robust growth, driven by increasing demand in key applications such as electrolyte additives for advanced batteries and as a crucial drug intermediate in pharmaceutical manufacturing. The market, estimated at $500 million in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 8% from 2025 to 2033, reaching approximately $950 million by 2033. This growth is fueled by the burgeoning electric vehicle (EV) industry, which necessitates high-performance battery electrolytes, and the expanding pharmaceutical sector's need for efficient and cost-effective drug synthesis. The high-purity segments (above 99% and above 99.9%) are expected to dominate the market due to stringent quality requirements in these sectors. While the market faces restraints such as fluctuating raw material prices and potential environmental concerns related to MMDS production, technological advancements in synthesis and purification methods are mitigating these challenges. Geographic expansion, particularly in rapidly developing Asian economies like China and India, further contributes to the market's positive outlook. The competitive landscape is characterized by a mix of established chemical manufacturers and specialized pharmaceutical companies. Key players are strategically focusing on capacity expansion, research and development of innovative synthesis routes, and strategic partnerships to solidify their market positions. Regional analysis indicates that North America and Europe currently hold significant market shares due to their well-established industries, but Asia-Pacific is anticipated to emerge as a major growth driver in the coming years, driven by the increasing manufacturing activity in the region. The ongoing shift towards sustainable practices and environmentally friendly production methods will play a significant role in shaping the future of the MMDS market, requiring companies to adapt and innovate to meet evolving regulatory requirements and consumer preferences.

Brazil Pay TV: Evolution of Pay TV Accesses by Technology (%): MMDS data was reported at 0.002 % in Dec 2020. This records a decrease from the previous number of 0.002 % for Nov 2020. Brazil Pay TV: Evolution of Pay TV Accesses by Technology (%): MMDS data is updated monthly, averaging 0.042 % from Jan 2012 (Median) to Dec 2020, with 108 observations. The data reached an all-time high of 1.794 % in Jan 2012 and a record low of 0.000 % in Jan 2020. Brazil Pay TV: Evolution of Pay TV Accesses by Technology (%): MMDS data remains active status in CEIC and is reported by National Telecommunications Agency. The data is categorized under Brazil Premium Database’s Telecommunication Sector – Table BR.TBA015: Pay TV: Evolution of Pay TV Accesses by Technology (Discontinued).

Density-driven mass movement deposits (MMDs) were mapped throughout the Quaternary sedimentary record of Lake El'gygytgyn (NE Siberia) using high-resolution acoustic data. Three different acoustic facies types were identified in the lake: (1) pelagic sediment, (2) plastic flow deposits and (3) turbidites. Deposits from plastic flows are dominantly present proximal to the lakes' slopes, whereas deposits from turbidity currents occur more spatially distributed. During glacial times, the distribution of MMDs was more uniform, while during interglacial periods, MMDs were deposited predominantly close to the slope of the northwestern area. Furthermore, the overall number of MMDs and accumulated sediment volume significantly varies between glacial/interglacial periods. About 1.6 times more MMDs were mapped during interglacials, contributing to a 3.5 times higher sediment volume. The main reason for this large difference is that a significant increase in plastic flows were formed during interglacials, which account for a much larger volume of sediments when compared with the glacial intervals characterized by increased amount of turbidites. It appears that the most important source areas for MMDs are located at the northern and western shores. Cycles of lake level changes caused by variations in climate conditions between glacials and interglacials are likely the main trigger mechanism for the generation of these MMDs. The climate-dependent genesis and partly erosive potential influencing the sedimentary record contain implications to consider for future paleo-environmental reconstructions in lacustrine settings. The supplementary data include high resolution versions of the figures of the article, a spreadsheet with calculated data for the statistics presented, an archive of mapped horizons in the seismic data used for gridding and the reference profile AWI-20038540.

All the movies are sorted by their degrees in a ascending order (horizontal ordinate). For a given movie , other movies are sorted by their similarities with in a ascending order (vertical ordinate) and the color depth denotes the value of similarity.

SimCoal simulationsThis compressed folder contains SimCoal simulations of 1-species datasets.DendroPy simulationsThis compressed folder contains simulations of 3-species and 6-species datasets obtained using DendroPy.countffrs.plThis perl script was used to perform haploweb analyses on the simulated datasets.countffrs_readme.txtFigure S1. Mismatch distributions computed for each simulated dataset.Figure S1 (MMDs on simulations).pdfFigure S2. Intra- (above) and interspecific mismatch distributions (below) computed on datasets simulated for 3 species.Figure S2 (MMDs on simulations).pdfFigure S3. Intra- (above) and interspecific mismatch distributions (below) computed on datasets simulated for 6 species.Figure S3 (MMDs on simulations).pdfFigure S4. Influence of mutation rate on the performance of GMYC-based methods.Figure S4 (phylogenetic uncertainty).pdf

Learn more about Market Research Intellect's Methylene Methanedisulfonate (MMDS) Sales Market Report, valued at USD 150 million in 2024, and set to grow to USD 250 million by 2033 with a CAGR of 7.5% (2026-2033).

Objective: To evaluate the efficacy and safety of eptinezumab, a humanized anti–calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM). Methods: The PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy–2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive intravenous (IV) eptinezumab 100 mg, eptinezumab 300 mg, or placebo, administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1–12. Results: Among treated participants (n = 1072), baseline mean MMDs was ~16.1 across groups. Treatment with eptinezumab 100 mg and 300 mg was associated with significant reductions in MMDs across weeks 1–12 compared with placebo (placebo, −5.6, 100 mg, −7.7, p < 0.0001 vs placebo; 300 mg, −8.2, p < 0.0001 vs placebo). Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients. Nasopharyngitis was the only TEAE reported for >2% of eptinezumab treated patients at an incidence of greater than 2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%). Conclusion: In patients with CM, eptinezumab 100 mg and 300 mg was associated with a significant reduction in MMDs from the day following IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile.

Численность населения, имеющего возможность принимать две телевизионные программы (с применением технологии MMDS, LMDS, MWS (MVDS)). Статистика с портала ЕМИСС (fedstat.ru).

Численность населения, имеющего возможность принимать Первый канал (с применением технологии MMDS, LMDS, MWS (MVDS)).

Статистика с портала ЕМИСС (fedstat.ru).

Learn more about Market Research Intellect's Methylene Methanedisulfonate (MMDS) Sales Market Report, valued at USD 150 million in 2024, and set to grow to USD 250 million by 2033 with a CAGR of 7.5% (2026-2033).

This database includes the raw data linked with the paper “Is early MIDAS reduction at 3 months the best indicator predictor for erenumab treatment continuation? A open-label trial”, published on The Journal of Headache and Pain.

In this paper, we described migraine disability, quantified as a MIgraine Disability ASsessment (MIDAS).

• A moderate to severe disability, MIDAS score  11, is required for prescription.

• Score reduction of at least 50% after the first three months (T3) is mandatory to continue treatment.

• Primary aim of this study:

• - to evaluate whether 50% MIDAS reduction at T3 (MIDASRes) is a reliable response predictor of one-year erenumab treatment (classified as a reduction of baseline MMDs 50%).

• The 50% reduction of monthly migraine days (MMD) at T3 Co-primary outcome

• Secondary outcomes:

• - the search of other predictors represents

• Methods:

• In this prospective, open-label study, 77 CM patients (mean age 49.8±9.5 years, chronicity history 13.1±10.3years, 93.5% of medication overuse headache) were treated with erenumab 70-140mg subcutaneous injections every 28 days for one year (T13). We assessed demographic and headache features, monthly migraine and headache days (MMD and MHDs respectively), days and doses of symptomatic intake. Patients also completed questionnaires evaluating migraine related disability (MIDAS and HIT-6), psychological comorbidities (HADS-A and HADS-D), quality of life (MSQ and 0 to 100 visual analogue scale) and allodynia (ASC-12). ANOVA for repeated measures was performed for quantifying erenumab efficacy and logistic regression model was used for evaluating one-year predictors of response.

• Results:

• Erenumab induced a sustained reduction of MMDs, MHDs and symptomatic intake during treatment. At T13 64.9% of patients presented MMDs baseline reduction 50% (RespondersT13). At T3, 55.8% of patients were MIDASRes. Contextually, 55.4% of patients were MMD Responders, these were also more likely to qualify as RespondersT13 when compared to non-responders (83.3% vs 42.9%; p=0.001). MMD response at T3 also demonstrated to be a predictor of long-term outcome according to a multivariate analysis ((Exp(B)=7.128; p=0.001)). When MIDAS reduction at T3 is considered as decision-making predictor of long-term outcome, 36.0% of patients who may benefit from 1-year erenumab administration are early excluded. By contrast, a lower percentage of Responders T13 (16%) would be discontinued if MIDASRes or MMD responders at T3 were alternatively considered.